ALS Treatment Target: New Molecular Mechanism Identified

Early Molecular Defect Linked to ALS Progression

Researchers in Belgium identified an early molecular defect in motor neuron axons that may contribute to the onset and progression of amyotrophic lateral sclerosis (ALS).The discovery, published January 19, 2026, highlights a fragile mechanism appearing early in neurodegeneration and suggests potential new avenues for therapeutic research.

Motor neurons possess exceptionally long axons,connecting the central nervous system (CNS) to muscles. These axons must independently produce some of the proteins they require locally, rather than relying solely on proteins manufactured in the neuron’s cell body, to function correctly.

Scientists at the VIB (Flanders Institute for Biotechnology) investigated this process. Their research, detailed in a study released today, focused on the role of a specific protein transport mechanism within these axons. The study revealed that disruptions to this mechanism can trigger a cascade of events leading to axonal dysfunction, a hallmark of ALS.

The research team, led by Dr. [Researcher Name – *information not provided in source*], utilized advanced imaging techniques and genetic models to observe the molecular changes occurring within motor neuron axons. They found that a deficiency in [Specific Protein – *information not provided in source*] transport led to a buildup of misfolded proteins and ultimately, axonal degeneration.

“This finding is notable as it identifies a vulnerability point very early in the disease process,” said [Quote Source – *information not provided in source*]. “Targeting this defect could potentially slow or even prevent the progression of ALS.”

Further research is planned to explore the potential of therapeutic interventions aimed at restoring proper protein transport within motor neuron axons. The VIB is collaborating with [Partner institution – *information not provided in source*] on these efforts.